Cover Image
市場調查報告書

美國的週邊靜脈導管 (PIVC) 市場

US Market Report for Peripheral Intravenous Catheters - MedCore

出版商 iData Research Inc. 商品編碼 360657
出版日期 內容資訊 英文 198 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的週邊靜脈導管 (PIVC) 市場 US Market Report for Peripheral Intravenous Catheters - MedCore
出版日期: 2016年05月01日 內容資訊: 英文 198 Pages
簡介

本報告提供美國的週邊靜脈導管 (PIVC) 市場相關調查分析,提供您疾病概要,產品的評估,市場概要,市場分析與預測,推動市場要素與阻礙要素,競爭分析等相關的系統性資訊。

第1章 摘要整理

第2章 調查手法

第3章 疾病概要

  • 基本結構
  • 血管病變·障礙
  • 患者的人口統計
    • 癌症
    • 末期腎功能衰竭
    • 糖尿病

第4章 產品的評估

  • 產品系列
    • 週邊靜脈導管 (PIVC)

第5章 週邊靜脈導管 (PIVC) 市場

  • 銷售額件數分析
  • 市場概要
  • 市場分析與預測
  • 推動因素·阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析

圖表

目錄
Product Code: iDATA_USVA16_MC_PIVC

Peripheral intravenous catheters (PIVCs) can be classified by catheter length. For any given gauge size there is a corresponding length or range of lengths that are classified as standard. If the length of a catheter exceeds the standard for a given gauge size, the PIVC is classified as long.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1. U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
  • 1.2. COMPETITIVE LANDSCAPE
  • 1.3. MARKET TRENDS
  • 1.4. KEY MARKET DEVELOPMENTS
  • 1.5. MARKETS INCLUDED
  • 1.6. PROCEDURES INCLUDED
  • 1.7. PROCEDURE CODES INVESTIGATED
  • 1.8. KEY REPORT UPDATES
  • 1.9. VERSION HISTORY

RESEARCH METHODOLOGY

  • 2.1. RESEARCH SCOPE
  • 2.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 3.1. BASIC ANATOMY
    • 3.1.1. Human Vascular System
  • 3.2. VASCULAR PATHOLOGY AND DISORDERS
    • 3.2.1. Cancer
    • 3.2.2. End-Stage Renal Disease
    • 3.2.3. Diabetes
    • 3.3. PATIENT DEMOGRAPHICS
      • 3.3.1. Cancer
        • 3.3.1.1. Digestive Cancer
        • 3.3.1.2. Genital Cancer
        • 3.3.1.3. Breast Cancer
        • 3.3.1.4. Respiratory Cancer
        • 3.3.1.5. Urinary Cancer
        • 3.3.1.6. Skin Cancer
        • 3.3.1.7. Lymphoma
        • 3.3.1.8. Endocrine System Cancer
        • 3.3.1.9. Leukemia
        • 3.3.1.10. Oral Cavity/Larynx
        • 3.3.1.11. Myeloma
        • 3.3.1.12. Brain/Other Nervous System
        • 3.3.1.13. Soft Tissue (including heart)
        • 3.3.1.14. Bones and Joints
        • 3.3.1.15. Eye and Orbit
      • 3.3.2. End-Stage Renal Disease
        • 3.3.2.1. End-Stage Renal Disease Incidence
          • 3.3.2.1.1. End-Stage Renal Disease Incident Cases by Modality
          • 3.3.2.1.2. End-Stage Renal Disease Incident Cases by Age Group
          • 3.3.2.1.3. End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
        • 3.3.2.2. Vascular Access Use at Hemodialysis Initiation
          • 3.3.2.2.1. Vascular Access Use During First Year of Hemodialysis
            • 3.3.2.2.1.1. Vascular Access Use During First Year of Hemodialysis by Age Group
            • 3.3.2.2.1.2. Vascular Access Use During First Year of Hemodialysis by Sex
          • 3.3.2.3. End-Stage Renal Disease Prevalence
            • 3.3.2.3.1. End-Stage Renal Disease Prevalent Cases by Modality
              • 3.3.2.3.1.1. Prevalent Hemodialysis Patients by Vascular Access Type
            • 3.3.2.3.2. End-Stage Renal Disease Prevalent Cases by Age Group
            • 3.3.2.3.3. End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
      • 3.3.3. Diabetes
        • 3.3.3.1. Diagnosed Diabetes Incidence Amongst Adults
          • 3.3.3.1.1. Diagnosed Diabetes Incidence Amongst Adults by State
        • 3.3.3.2. Diagnosed Diabetes Prevalence Amongst Adults
          • 3.3.3.2.1. Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
          • 3.3.3.2.2. Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
          • 3.3.3.2.3. Diagnosed Diabetes Prevalence Amongst Adults by State and Gender

    PRODUCT ASSESSMENT

    • 4.1. PRODUCT PORTFOLIOS
      • 4.1.1. Peripheral Intravenous Catheters
        • 4.1.1.1. Introduction
        • 4.1.1.2. Access Scientific
          • 4.1.1.2.1. POWERWAND®
        • 4.1.1.3. AngioDynamics
          • 4.1.1.3.1. BioFlo®
        • 4.1.1.4. Argon Medical
          • 4.1.1.4.1. First Midcath™
          • 4.1.1.4.2. L-Cath™
        • 4.1.1.5. B. Braun
          • 4.1.1.5.1. Introcan Safety®
        • 4.1.1.6. Becton Dickinson
          • 4.1.1.6.1. Nexiva™
          • 4.1.1.6.2. Saf-T-Intima™
          • 4.1.1.6.3. Autoguard™
        • 4.1.1.7. C.R. Bard
          • 4.1.1.7.1. AccuCath®
          • 4.1.1.7.2. PowerGlide®
          • 4.1.1.7.3. Bard® Poly
          • 4.1.1.7.4. Other Midline Offerings
        • 4.1.1.8. GaltNeedleTech
          • 4.1.1.8.1. Nexus™
        • 4.1.1.9. Medcomp
          • 4.1.1.9.1. Medcomp® Midline
        • 4.1.1.10. MediKit
          • 4.1.1.10.1. Supercath™
        • 4.1.1.11. Neo Medical
          • 4.1.1.11.1. PowerStick™
          • 4.1.1.11.2. Neo-Magic®
        • 4.1.1.12. Nipro Medical
          • 4.1.1.12.1. Nipro™ IV Catheter
        • 4.1.1.13. Retractable Technologies, Inc.
          • 4.1.1.13.1. VanishPoint®
        • 4.1.1.14. Smiths Medical
          • 4.1.1.14.1. ViaValve™
          • 4.1.1.14.2. PROTECTIV®
          • 4.1.1.14.3. ACUVANCE®
          • 4.1.1.14.4. Other PIVC offerings
        • 4.1.1.15. Tangent Medical
          • 4.1.1.15.1. NovaCath™
        • 4.1.1.16. Teleflex Medical
          • 4.1.1.16.1. ARROW®
          • 4.1.1.16.2. TwinCath®
        • 4.1.1.17. Terumo
          • 4.1.1.17.1. SurFlash®
          • 4.1.1.17.2. SURFLO®
        • 4.1.1.18. Vygon
          • 4.1.1.18.1. Leader-Flex™

PERIPHERAL INTRAVENOUS CATHETER MARKET

  • 5.1. UNIT ANALYSIS
    • 5.1.1. Peripheral Intravenous Catheter Units Sold by Length
    • 5.1.2. Peripheral Intravenous Catheter Units Sold by Insertion Site
    • 5.1.3. Peripheral Intravenous Catheter Units Sold by Insertion Technique
  • 5.2. MARKET OVERVIEW
    • 5.2.1. Peripheral Intravenous Catheter Market Overview by Device Type
    • 5.2.2. Peripheral Intravenous Catheter Market Overview by Setting
  • 5.3. MARKET ANALYSIS AND FORECAST
    • 5.3.1. Total Peripheral Intravenous Catheter Market
    • 5.3.2. Peripheral Intravenous Catheter Market by Device Type Conventional Peripheral In
      • 5.3.2.1. travenous Catheter Market
      • 5.3.2.2. Total Safety Peripheral Intravenous Catheter Market
        • 5.3.2.2.1. Blood Control Safety Peripheral Intravenous Catheter Market
          • 5.3.2.2.1.1. Integrated Blood Control Safety Peripheral Intravenous Catheter Market
          • 5.3.2.2.1.2. Non-Integrated Blood Control Safety Peripheral Intravenous Catheter Market
        • 5.3.2.2.2. Non-Blood Control Safety Peripheral Intravenous Catheter Market
          • 5.3.2.2.2.1. Non-Blood Control Active Safety Peripheral Intravenous Catheter Market
          • 5.3.2.2.2.2. Non-Blood Control Passive Safety Peripheral Intravenous Catheter Market
        • 5.3.2.3. Total Midline Catheter Market
          • 5.3.2.3.1. Conventional Midline Catheter Market
          • 5.3.2.3.2. AST Midline Catheter Market
      • 5.3.3. Peripheral Intravenous Catheter Market by Setting
        • 5.3.3.1. Acute Care Peripheral Intravenous Catheter Market
        • 5.3.3.2. Total Alternate Care Peripheral Intravenous Catheter Market
          • 5.3.3.2.1. Home Care Peripheral Intravenous Catheter Market
          • 5.3.3.2.2. Outpatient and Nursing Home Care Peripheral Intravenous Catheter Market
  • 5.4. DRIVERS AND LIMITERS
    • 5.4.1. Market Drivers
    • 5.4.2. Market Limiters
  • 5.5. COMPETITIVE MARKET SHARE ANALYSIS

LIST OF CHARTS

  • Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012-2022
  • Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
  • Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
  • Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
  • Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
  • Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
  • Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
  • Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
  • Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
  • Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
  • Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
  • Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
  • Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-28: Male Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015 83
  • Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015 ....
  • Chart 3-61: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Chart 5-1: Peripheral Intravenous Catheter Units Sold by Length, U.S., 2015
  • Chart 5-2: Peripheral Intravenous Catheter Units Sold by Length, U.S., 2022
  • Chart 5-3: Peripheral Intravenous Catheter Units Sold by Insertion Site, U.S., 2015
  • Chart 5-4: Peripheral Intravenous Catheter Units Sold by Insertion Site, U.S., 2022
  • Chart 5-5: Peripheral Intravenous Catheter Units Sold by Insertion Technique, U.S., 2015
  • Chart 5-6: Peripheral Intravenous Catheter Market by Device Type, U.S., 2012-2022
  • Chart 5-7: Peripheral Intravenous Catheter Market Breakdown by Device Type, U.S., 2015
  • Chart 5-8: Peripheral Intravenous Catheter Market Breakdown by Device Type, U.S., 2022
  • Chart 5-9: Peripheral Intravenous Catheter Market by Setting, U.S., 2012-2022
  • Chart 5-10: Peripheral Intravenous Catheter Market Breakdown by Setting, U.S., 2015
  • Chart 5-11: Peripheral Intravenous Catheter Market Breakdown by Setting, U.S., 2022
  • Chart 5-12: Total Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-13: Conventional Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-14: Total Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-15: Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-16: Integrated Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-17: Non-Integrated Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-18: Non-Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-19: Non-Blood Control Active Safety Peripheral Intravenous Catheter Market, U.S. 2012-2022
  • Chart 5-20: Non-Blood Control Passive Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-21: Total Midline Catheter Market, U.S., 2012-2022
  • Chart 5-22: Conventional Midline Catheter Market, U.S., 2012-2022
  • Chart 5-23: AST Midline Catheter Market, U.S., 2012-2022
  • Chart 5-24: Acute Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-25: Total Alternate Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-26: Home Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-27: Outpatient and Nursing Home Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Chart 5-28: Leading Competitors, Peripheral Intravenous Catheter Market, U.S., 2015

LIST OF FIGURES

  • Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
  • Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
  • Figure 0-3: Companies Researched in Report, U.S., 2015
  • Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
  • Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012-2015
  • Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
  • Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
  • Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
  • Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
  • Figure 0-10: Procedural Codes, U.S., 2015
  • Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
  • Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
  • Figure 0-13: Version History
  • Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
  • Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013-2014
  • Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013-2014
  • Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
  • Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
  • Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997-2015
  • Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
  • Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
  • Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
  • Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
  • Figure 5-1: Peripheral Intravenous Catheter Units Sold by Length, U.S., 2012-2022
  • Figure 5-2: Peripheral Intravenous Catheter Units Sold by Insertion Site, U.S., 2012-2022
  • Figure 5-3: Peripheral Intravenous Catheter Units Sold by Insertion Technique, U.S., 2015
  • Figure 5-4: Peripheral Intravenous Catheter Market by Device Type, U.S., 2012-2022 (US$M)
  • Figure 5-5: Peripheral Intravenous Catheter Market by Setting, U.S., 2012-2022 (US$M)
  • Figure 5-6: Total Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-7: Conventional Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-8: Total Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-9: Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-10: Integrated Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-11: Non-Integrated Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-12: Non-Blood Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-13: Non-Blood Active Control Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-14: Non-Blood Control Passive Safety Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-15: Total Midline Catheter Market, U.S., 2012-2022
  • Figure 5-16: Conventional Midline Catheter Market, U.S., 2012-2022
  • Figure 5-17: AST Midline Catheter Market, U.S., 2012-2022
  • Figure 5-18: Acute Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-19: Total Alternate Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-20: Home Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-21: Outpatient and Nursing Home Care Peripheral Intravenous Catheter Market, U.S., 2012-2022
  • Figure 5-22: Drivers and Limiters, Peripheral Intravenous Catheter Market, U.S., 2015
  • Figure 5-23: Leading Competitors, Peripheral Intravenous Catheter Market, U.S., 2015
Back to Top